• Explore /
  • Poster
  • / Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003.

Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003.

Abstract Poster

Authors

null

Hartmut Goldschmidt

Universitätsklinikum Heidelberg, Heidelberg, Germany

Hartmut Goldschmidt , Meletios A. Dimopoulos , Katja C. Weisel , Philippe Moreau , Martha Lacy , Kevin W. Song , Michel Delforge , Lionel Karlin , Anne Banos , Albert Oriol Rocafiguera , Xin Yu , Lars Sternas , Christian Jacques , Mohamed H. Zaki , Jesùs F. San-Miguel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT01311687

Citation

J Clin Oncol 31, 2013 (suppl; abstr 8528)

DOI

10.1200/jco.2013.31.15_suppl.8528

Abstract #

8528

Poster Bd #

8

Abstract Disclosures

Similar Posters

First Author: Katja C. Weisel

First Author: Philippe Moreau

First Author: Katja Weisel

First Author: David Samuel DiCapua Siegel